Global Ophthalmic Drugs Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 30.37 Million |
 Market Size (Forecast Year) |
USD 53.36 Million |
 CAGR |
% |
| Major Markets Players |
|
全球眼科药物市场，按药物（抗炎、抗感染、抗青光眼、抗过敏、抗血管内皮生长因子等）、疾病（干眼症、过敏、青光眼、眼部感染、感染、视网膜疾病、葡萄膜炎等）、剂型（凝胶、眼溶液和悬浮液、胶囊和片剂、眼药水和软膏）、给药途径（局部、局部眼部和全身）、产品类型（处方药和非处方药）和产品（品牌药和仿制药）、最终用户（医院、专科诊所等）、分销渠道（直接和间接）划分 - 行业趋势和预测到 2031 年。
眼科药物市场分析及规模
在尖端方法和技术的推动下，眼科药物市场正在快速发展。缓释植入物和纳米技术等创新正在彻底改变治疗效果和患者依从性。这种增长是对全球眼部疾病增加的反应；世界卫生组织 2021 年 10 月的报告强调，近 22 亿人受到视力障碍的影响。这一统计数据强调了持续研发的迫切需要，以有效满足不断增长的医疗保健需求。市场的发展轨迹凸显了向创新解决方案的关键转变，这些解决方案有望改善治疗效果并改善全球数百万人的生活质量。
2023 年全球眼科药物市场规模为 3037 万美元，预计到 2031 年将达到 5336 万美元，预测期内（2024 年至 2031 年）的复合年增长率为 7.3%。这表明市场价值。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
报告范围和市场细分
|
报告指标 |
细节 |
|
预测期 |
2024 至 2031 年 |
|
基准年 |
2023 |
|
历史岁月 |
2022 (可定制为 2016-2021) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
药物（抗炎、抗感染、抗青光眼、抗过敏、抗血管内皮生长因子等）、疾病（干眼症、过敏、青光眼、眼部感染、感染、视网膜疾病、葡萄膜炎等）、剂型（凝胶、眼溶液和混悬液、胶囊和片剂、眼药水和软膏）、给药途径（局部、眼部和全身）、产品类型（处方药和非处方药）和产品（品牌药和仿制药）、最终用户（医院、专科诊所等）、分销渠道（直接和间接） |
|
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
|
Market Players Covered |
Akorn Operating Company LLC. (U.S.), Johnson & Johnson Services, Inc.(U.S.), Mitotech Ltd (Germany), AbbVie Inc. (U.S.), Santen Pharmaceutical Co., Ltd. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Bausch Health Companies Inc. (Canada.), AERIE PHARMACEUTICALS, INC. (U.S.), Novartis AG (Switzerland), Merck & Co. Inc. (U.S.), Bayer AG (Germany), and F. Hoffmann-La Roche Ltd (Switzerland) |
|
Market Opportunities |
|
Market Definition
Ophthalmic drugs are medications designed for treating eye conditions. They come in various forms such as eye drops, ointments, or gels. These drugs are used to alleviate symptoms such as dryness, itching, or infections of the eyes. Some ophthalmic drugs are also prescribed to manage conditions such as glaucoma or inflammation. Proper application and adherence to dosage instructions are crucial for their effectiveness.
Ophthalmic Drugs Market Dynamics
Drivers
- Increasing Prevalence of Eye Diseases
The increasing prevalence of eye diseases such as glaucoma, cataracts, diabetic retinopathy, and age-related macular degeneration is significantly driving the demand for ophthalmic drugs. For instance, the rise in diabetic retinopathy cases, driven by the global diabetes epidemic, necessitates more advanced treatments, boosting the market. Consequently, the growing patient pool for these conditions is propelling market growth for innovative and effective ophthalmic therapies.
- Technological Advancements in Drug Delivery
Technological advancements in drug delivery, such as sustained-release implants and nanoparticle formulations, significantly enhance the efficacy and patient compliance of ophthalmic drugs. For instance, sustained-release implants for glaucoma provide consistent medication over months, reducing the need for frequent eye drops. These innovations improve treatment outcomes and convenience, driving the ophthalmic drugs market by meeting patient needs more effectively and expanding treatment options.
Opportunities
- Growing Awareness and Screening Programs
Growing awareness about eye health and expanded screening programs have led to earlier diagnosis and treatment of eye conditions, significantly fueling the demand for ophthalmic drugs. For instance, initiatives such as World Glaucoma Week have increased public awareness, prompting more people to undergo regular eye check-ups. This proactive approach results in timely intervention, thereby driving the market for ophthalmic drugs as more individuals seek treatment for newly diagnosed conditions.
- Government Initiatives and Policies
Government initiatives and policies, such as subsidies and public health campaigns, are instrumental in reducing the burden of eye diseases, thereby driving market growth for ophthalmic drugs. For instance, the U.S. government's Healthy People 2030 initiative aims to improve eye health through preventive services and education, increasing the demand for treatments. Such supportive measures facilitate better access to ophthalmic care and stimulate the market's expansion.
Restraints/Challenges
- Complex Manufacturing Processes
Complex manufacturing processes in the ophthalmic drugs market pose significant challenges. High precision is essential in drug formulation and production, demanding advanced technologies and skilled personnel. Additionally, stringent sterility and stability requirements must be met to ensure product safety and efficacy. These factors lead to increased production costs and time, further complicating the development and availability of ophthalmic drug.
- High Development Costs
High development costs are a significant restraint in the ophthalmic drugs market. Expensive research and development investments and the high cost of clinical trials and regulatory compliance create substantial financial barriers. These costs hinder the market by limiting the ability of smaller companies to compete and slowing the introduction of new drugs. Consequently, innovation is stifled, and market growth is restricted due to these financial burdens.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- 2023 年 2 月，拜耳公司向欧盟提交了 8 毫克阿柏西普的监管审批，用于治疗两种主要的视网膜疾病。此次审批对拜耳来说意义重大，因为阿柏西普有望为患有这些疾病的患者提供一种先进的治疗选择，有可能改善欧洲许多患者的视力结果和生活质量
- 2023 年 1 月，Bausch Health Companies, Inc. 在美国推出了 PreserVision AREDS 2 Formula 迷你凝胶眼部维生素。该产品专为中度至晚期老年性黄斑变性 (AMD) 患者配制。迷你凝胶形式提供了一种比传统眼部维生素更易于吞咽的替代品，旨在提高患者的依从性并有效支持眼部健康
- 2022 年 4 月，诺华旗下 Sandoz 公司在美国推出其仿制药组合眼药水 0.2%/0.5% 酒石酸布莫尼定/马来酸噻吗洛尔滴眼液。该产品是 AbbVie 的 COMBIGAN 的 AB 级仿制药，旨在降低眼高压患者的眼压。该产品的上市提供了更实惠的治疗选择，同时保持了疗效和安全性标准
- 2022 年 3 月，Théa Pharma 从 Akorn Operating Company LLC 收购了七种品牌眼科产品。此次战略收购增强了 Théa Pharma 的产品组合，并巩固了其在美国市场的地位。新收购的产品有望满足眼科护理专家的多样化需求，使 Théa Pharma 能够为各种眼科疾病提供全面的解决方案
眼科药物市场范围
市场根据药物、疾病、剂型、给药途径、产品类型、产品、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
药物
- 消炎（药
- 非甾体抗炎药
- 类固醇
- 抗感染
- 抗真菌
- 抗菌
- 其他的
- 抗青光眼
- 阿尔法激动剂
- β受体阻滞剂
- 前列腺素类似物
- 联合用药
- 其他的
- 抗过敏
- 抗血管内皮生长因子
- 其他的
疾病
- 干眼症
- 过敏
- 青光眼
- 眼部感染
- 感染
- 视网膜疾病
- 葡萄膜炎
- 啫喱
- 眼用溶液和悬浮液
- 胶囊和药片
- 眼药水
- 软膏
- 其他的
剂型
- 啫喱
- 眼用溶液和悬浮液
- 胶囊和药片
- 眼药水
- 软膏
给药途径
- 主题
- 视网膜疾病
- 结膜下
- 玻璃体内
- 球后
- 前房内
- 局部眼科
- 系统性
产品类型
- 处方药
- 场外交易
产品
- 品牌药物
- 仿制药
最终用户
- 医院
- 专科诊所
- 其他的
分销渠道
- 直接的
- 间接
眼科药物市场区域分析/见解
对市场进行分析，并按国家、药物、疾病、剂型、给药途径、产品类型、产品、最终用户和分销渠道提供市场规模洞察和趋势，如上所述。
市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
由于眼部疾病的发病率不断上升以及人们的意识不断提高，北美的眼科药物市场一直呈现积极增长态势。爱尔康、辉瑞和博士伦等主要公司的研发以及频繁的产品发布进一步推动了该地区的增长。
亚太地区患者基数大、发病率高、本土公司崛起，有望主导眼科药物市场。主要参与者的战略举措进一步增强了这一重要医疗保健领域的区域增长前景。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
医疗保健基础设施增长安装基础和新技术渗透
该市场还为您提供每个国家/地区资本设备医疗支出增长、市场上不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。
竞争格局和眼科药物市场份额分析
市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
市场上的一些主要参与者包括：
- Akorn Operating Company LLC.（美国）
- 强生服务公司（美国）
- Mitotech Ltd (德国)
- AbbVie Inc.（美国）
- 参天制药株式会社（日本）。
- Teva Pharmaceutical Industries Ltd.（以色列）
- Bausch Health Companies Inc.（加拿大）
- AERIE PHARMACEUTICALS, INC.（美国）
- 诺华公司（瑞士）
- 默克公司（美国）
- 拜耳公司（德国）
- F. Hoffmann-La Roche Ltd（瑞士）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
